For 50 years now, the German Pharmaceutical Industry Association (BIP) has been analyzing pharmaceutical data. (BIP) has been analyzing pharmaceutical data for 50 years; this year, the anniversary edition is „Pharma Data 2020“. According to this data, pharmaceutical spending is at the same level as it has been for the past 30 years and accounts for 15 to 16 percent of all SHI total spending. A great deal of money is invested in research and development; 13 percent of sales, more than in any other industry.
The industry criticizes the fact that it is nevertheless under constant financial pressure from discounts, rebates, reference prices and moratoriums. Regulatory interventions through mandatory discounts and legally mandated deferrals are a burden on the pharmaceutical industry, which is important for research in order to be able to innovatively counteract rare diseases with novel drugs, for example. The analysis of BPI Pharma data clearly shows that discount agreements with health insurers have led to four billion euros in savings this year, although two billion euros have been targeted since the Act on the Reorganization of the Pharmaceutical Market (AMNOG) came into force in 2011. In 2013, on the other hand, it was only 144 million euros that have already helped to curb the rapidly rising expenditure on medicines. The introduction of reference prices will add another 8.2 billion euros in annual savings. Despite this, the pharmaceutical industry continues to be subject to financial pressure from mandatory discounts and price moratoriums, but nevertheless makes important contributions to issues such as SHI spending, drug prices, research, production and the importance of the pharmaceutical industry for the safe and reliable supply of medicines in Germany.
Source: gesundheit-adhoc.de